Particle.news
Download on the App Store
13 ARTICLES
·
4d ago

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

The FDA describes an evidence‑driven study now in a data‑gathering phase with no projected timeline.

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
Image
FDA Commissioner Marty Makary
Image

Overview

  • Bloomberg, citing anonymous sources, reported that Commissioner Marty Makary asked to postpone a comprehensive safety review of mifepristone until after the 2026 midterm elections.
  • Leaders of Susan B. Anthony Pro‑Life America and Live Action publicly called for Makary to be fired and urged reinstatement of in‑person dispensing rules for the abortion drug.
  • HHS officials and the White House rejected claims of political slow‑walking, saying rigorous scientific reviews require time to ensure accuracy.
  • Makary told The Daily Signal the FDA is conducting an ongoing review, is in the data acquisition phase, and cannot predict a timeframe, adding he is personally responsible for the analysis.
  • Sen. Josh Hawley escalated oversight with a Dec. 10 letter seeking answers by Dec. 15 on the scope of the review, any delays, and whether the FDA will revert to in‑person dispensing requirements.